Trial Profile
Antibody-dependent cell cytotoxicity induced by vaccination with racotumomab in patients with non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Sep 2017
Price :
$35
*
At a glance
- Drugs Racotumomab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 28 Sep 2017 New trial record
- 09 Sep 2017 Results presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference